NO20062916L - Overflatelokaliserte campylobacter jejuni-polypeptider - Google Patents

Overflatelokaliserte campylobacter jejuni-polypeptider

Info

Publication number
NO20062916L
NO20062916L NO20062916A NO20062916A NO20062916L NO 20062916 L NO20062916 L NO 20062916L NO 20062916 A NO20062916 A NO 20062916A NO 20062916 A NO20062916 A NO 20062916A NO 20062916 L NO20062916 L NO 20062916L
Authority
NO
Norway
Prior art keywords
campylobacter
polypeptides
campylobacter jejuni
localized
surface localized
Prior art date
Application number
NO20062916A
Other languages
English (en)
Norwegian (no)
Inventor
Janne Skaarup Crawford
Pia Nyborg Nielsen
Tatyana A Prokhorova
Petra Schrotz-King
Original Assignee
Ace Biosciences As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ace Biosciences As filed Critical Ace Biosciences As
Publication of NO20062916L publication Critical patent/NO20062916L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20062916A 2003-11-21 2006-06-21 Overflatelokaliserte campylobacter jejuni-polypeptider NO20062916L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301726 2003-11-21
US52461703P 2003-11-25 2003-11-25
PCT/DK2004/000803 WO2005049641A2 (en) 2003-11-21 2004-11-19 Surface-located campylobacter jejuni polypeptides

Publications (1)

Publication Number Publication Date
NO20062916L true NO20062916L (no) 2006-08-21

Family

ID=43426113

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062916A NO20062916L (no) 2003-11-21 2006-06-21 Overflatelokaliserte campylobacter jejuni-polypeptider

Country Status (14)

Country Link
US (1) US20070178110A1 (de)
EP (1) EP1694697B1 (de)
JP (1) JP2008501625A (de)
KR (1) KR20060129229A (de)
CN (1) CN1906210A (de)
AT (1) ATE493431T1 (de)
AU (1) AU2004291213B2 (de)
CA (1) CA2546873A1 (de)
DE (1) DE602004030824D1 (de)
DK (1) DK1694697T3 (de)
ES (1) ES2358804T3 (de)
NO (1) NO20062916L (de)
PL (1) PL1694697T3 (de)
WO (1) WO2005049641A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765861B1 (de) * 2004-06-18 2012-02-15 Enkam Pharmaceuticals A/S Fgfr-bindende peptide
EA013016B1 (ru) * 2005-03-31 2010-02-26 Лейден Юниверсити Медикал Сентер Способы и средства диагностики, профилактики и лечения инфекций mycobacterium и заболевания туберкулезом
US9047864B2 (en) 2009-07-16 2015-06-02 Washington State University Antigen compositions and methods of inhibiting Campylobacter jejuni bacterial infection and uses of the antigen compositions
CA2800830C (en) 2010-06-09 2020-09-08 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce campylobacter infection
CN104159601B (zh) 2012-02-01 2017-05-24 代表亚利桑那大学的亚利桑那董事会 弯曲杆菌属免疫原性组合物及其用途
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR20190015712A (ko) 2016-05-03 2019-02-14 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
CN110520153B (zh) * 2017-01-27 2024-04-02 佛罗里达大学研究基金公司 在禽类中控制肠道沙门氏菌和减少弯曲杆菌的食品安全疫苗
US12297258B2 (en) * 2018-07-17 2025-05-13 Humabs Biomed Sa Antibodies against Campylobacter species

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
CA2286306A1 (en) * 1997-04-01 1998-10-08 Human Genome Sciences, Inc. Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
AU3458299A (en) * 1998-03-31 1999-10-18 United States Of America, As Represented By The Secretary Of Agriculture, The Monoclonal antibodies against (campylobacter jejuni) and (campylobacter coli) outer membrane antigens
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2000351735A (ja) * 1999-04-09 2000-12-19 Akzo Nobel Nv カンピロバクターワクチン
CA2296869A1 (en) * 2000-01-24 2001-07-24 Angela Joe A surface-exposed lipoprotein to campylobacter jejuni involved in adherence to hep-2 cells
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms

Also Published As

Publication number Publication date
HK1097854A1 (en) 2007-07-06
DK1694697T3 (da) 2011-04-18
PL1694697T3 (pl) 2011-05-31
EP1694697A2 (de) 2006-08-30
ES2358804T3 (es) 2011-05-13
AU2004291213A1 (en) 2005-06-02
US20070178110A1 (en) 2007-08-02
CN1906210A (zh) 2007-01-31
KR20060129229A (ko) 2006-12-15
AU2004291213B2 (en) 2011-09-08
EP1694697B1 (de) 2010-12-29
WO2005049641A2 (en) 2005-06-02
JP2008501625A (ja) 2008-01-24
ATE493431T1 (de) 2011-01-15
WO2005049641A3 (en) 2005-10-20
DE602004030824D1 (de) 2011-02-10
CA2546873A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2004083816A3 (en) Loss of heterozygosity of the dna markers in the 12q22-23 region
NO20065084L (no) Interferon-alfa polypeptider og konjugater
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
WO2002092836A3 (en) Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
NO20006681D0 (no) Fremgangsmåte ved tidlig diagnose av karsinomer
WO2000029008A3 (en) Hiv-specific t-cell induction
NO20080590L (no) Humane, monoklonale antistoffer mot programmert dodsligand (PD-L1)
DK1576967T3 (da) Rekombinant protein, der bærer epitoper fra det humane papillomvirus indsat i et adenylatcyclaseprotein eller et fragment deraf samt dets terapeutiske anvendelse
WO2006063042A3 (en) Selecting patients for therapy with a her inhibitor
IL188460A0 (en) Diagnostic methods and compositions for diagnosing and treating influenza
WO2006103666A3 (en) Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
TR199800613A1 (xx) Nezle A��s�.
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EP1281755A3 (de) Humane cyp2d6 Genvarianten
NO20052363L (no) Interferon-alfa polypeptider og konjugater
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
WO2003055917A3 (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
DK1694697T3 (da) Overfladelokaliserede Campylobacter jejuni-polypeptider
DE602006010544D1 (de) Mit dem risiko von obesität und typ-2-diabetes assoziierter haplotyp des gens enpp1 (pc1) und anwendungen davon
WO2006062402A3 (en) Heat shock proteins (hsp) and supraventricular arrhythmia
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
NO20063375L (no) Agonist-anti-trkC-antistoffer og fremgangsmater for a anvende disse
DE60132443D1 (de) In lebenden zielzellen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application